News
Thousands in England set to benefit from ‘repurposed’ drug to prevent breast cancer
Around 2,000 cases would be prevented if 25 per cent of eligible women in England take up the offer, according to NHS England

Tens of thousands of women in England could benefit from a “repurposed” NHS drug that could help prevent breast cancer.
Anastrozole, which has been used for many years as a breast cancer treatment, has been licensed as a preventive option, in a move that could help prevent around 2,000 cases of breast cancer in England.
The drug, which is off-patent, has been shown in trials to reduce the incidence of the disease in post-menopausal women at increased risk of the disease by almost 50 per cent.
It was first recommended as a preventive option by the National Institute for Health and Care Excellence in 2017, however, with the treatment being unlicensed in this use, uptake has remained low.
An estimated 289,000 women could be eligible for the drug.
While not all patients will choose to take it, it is estimated that if 25 per cent do, around 2,000 cases of breast cancer in England could potentially be prevented.
NHS chief executive, Amanda Pritchard, said: “It’s fantastic that this vital risk-reducing option could now help thousands of women and their families avoid the distress of a breast cancer diagnosis.
“Allowing more women to live healthier lives, free of breast cancer is truly remarkable, and we hope that licensing anastrozole for a new use today represents the first step to ensuring this risk-reducing option can be accessed by all who could benefit from it.
“This is the first drug to be repurposed through a world-leading new programme to help us realise the full potential of existing medicines in new uses to save and improve more lives on the NHS.
“Thanks to this initiative, we hope that greater access to anastrozole could enable more women to take risk-reducing steps if they’d like to, helping them live without fear of breast cancer.”
Lesley-Ann Woodhams, 61, was offered anastrozole off-label for the prevention of breast cancer due to being at increased risk of developing the disease, and having a family history of breast cancer. She completed the full five-year course of anastrozole in January.
She said: “Taking anastrozole was an easy decision for me, as I’d watched my mum battle breast cancer and my risk was very high.
“Anastrozole reduced my risk of developing breast cancer, meaning I could live a life without constantly worrying or giving a thought to what could be if I’d developed breast cancer.
“It really was a gift, it gave my family and myself peace of mind and more importantly, a continued future to look forward to. I’m grateful for every day I took this drug – it was life-changing.”
She added: “Anastrozole has allowed me to continue living my life as I’d planned.”
Breast cancer remains the most common cancer in England, with 47,000 people being diagnosed each year.
Anastrozole is the first medicine to be repurposed through a new multi-agency national programme that looks at using existing medicines in new ways to benefit patients and the NHS.
The treatment is an aromatase inhibitor and works by cutting down the amount of the hormone oestrogen that a patient’s body makes by blocking an enzyme called “aromatase”.
Health minister, Will Quince, said: “Breast cancer is the most common cancer in the UK so I’m delighted that another effective drug to help to prevent this cruel disease has now been approved.
“We’ve already seen the positive effect Anastrozole can have in treating the disease when it has been detected in post-menopausal women and now we can use it to stop it developing at all in some women.
“This is a great example of NHS England’s innovative Medicines Repurposing Programme supporting the development of new ways for NHS patients to benefit from existing treatments.”
Baroness Delyth Morgan, chief executive at the charity Breast Cancer Now, said: “The extension of anastrozole’s licence to cover it being used as a risk-reducing treatment is a major step forward that will enable more eligible women with a significant family history of breast cancer, to reduce their chance of developing the disease.
“For the past decade, Breast Cancer Now has been tirelessly campaigning with clinicians, researchers and patients for drugs that are found to be effective and safe in new uses to reach people who could benefit, and we were thrilled when NHS England set up the Medicines Repurposing Programme.
“Anastrozole was the first drug to be supported by the programme and this paves the way for improving access to risk-reducing drugs,” she continued.
“We look forward to continuing our work with NHS England to further improve access to these drugs for everyone eligible.”
To receive the Femtech World newsletter, sign up here.
Menopause
AI maps how reproductive organs age differently during menopause
Cancer
Ovarian cancer cases rising among younger adults, study finds

Ovarian cancer cases are rising among younger adults in England, with bowel cancer showing a similar pattern, a new study suggests.
Researchers said excess weight is a key contributor, but is unlikely on its own to explain the pattern.
The authors wrote: “These patterns suggest that while similar risk factors across ages are likely, some cancers may have age-specific exposures, susceptibilities, or differences in screening and detection practices.”
They added: “Although overweight and obesity are linked to 10 of the 11 cancers evaluated and account for a substantial proportion of cancer cases, both BMI-attributable and BMI-non-attributable incidence rates have increased, though the latter more slowly, suggesting other contributors.”
The study analysed cancer incidence, meaning new diagnoses, in England between 2001 and 2019 across more than 20 cancer types, comparing adults aged 20 to 49 with those aged 50 and over.
Among younger women, cases of 16 out of 22 cancers increased significantly over the period, while among younger men, 11 out of 21 cancers increased significantly.
In particular, there was a significant rise in 11 cancers with known behavioural risk factors among adults under 50. These were thyroid, multiple myeloma, liver, kidney, gallbladder, bowel, pancreatic, endometrial, mouth, breast and ovarian cancers.
Rates of all 11 also rose significantly among adults aged 50 and over, with the notable exceptions of bowel and ovarian cancer.
Five cancers, endometrial, kidney, pancreatic, multiple myeloma and thyroid cancer, increased significantly faster in younger than in older women, while multiple myeloma increased faster in younger than in older men.
The researchers looked at established risk factors including smoking, alcohol intake, diet, physical inactivity and body mass index, a measure used to assess whether someone is underweight, a healthy weight, overweight or obese.
With the exception of mouth cancer, all 11 cancers were associated with obesity. Six, liver, bowel, mouth, pancreatic, kidney and ovarian, were also linked to smoking.
Four, liver, bowel, mouth and breast, were associated with alcohol intake. Three, bowel, breast and endometrial, were linked to physical inactivity, and one, bowel, was associated with dietary factors.
But apart from excess weight, trends in those risk factors over the past one to two decades were stable or improving among younger adults.
That suggests other factors may also play a part, including reproductive history, early-life or prenatal exposures, and changes in diagnosis and detection.
The study noted that red meat consumption fell among younger adults, while fibre intake remained stable or slightly improved in both sexes between 2009 and 2019, although more than 90 per cent of younger adults were still not eating enough fibre in 2018.
Established behavioural risk factors accounted for a substantial share of cancer cases.
Excess weight was the risk factor associated with most cancers in 2019, ranging from 5 per cent for ovarian cancer to 37 per cent for endometrial cancer.
The researchers said the findings were based on observational data, meaning the study could identify patterns but could not prove cause and effect.
They also noted there were no consistent long-term national data for several risk factors, that the analysis was limited to England rather than the UK, and that cancer remains far more common overall in older adults despite the rise in cases among younger people.
Pregnancy
Early miscarriage care could prevent 10,000 pregnancy losses a year, study finds
Entrepreneur7 days agoFuture Fertility raises Series A financing to scale AI tools redefining fertility care worldwide
Entrepreneur4 weeks agoThree sessions that show exactly where women’s health is heading in 2026
Pregnancy4 weeks agoHow NIPT has evolved and what AI NIPT means in 2026
News4 weeks agoTwo weeks left to make your mark in women’s cardiovascular health
Diagnosis2 weeks agoFuture Fertility partners with Japan’s leading IVF provider, Kato Ladies Clinic
Mental health1 week agoLifting weights shows mental health and cognitive benefits in older women, study finds
Menopause2 weeks agoMore research needed to understand link between brain fog and menopause, expert says
News4 weeks agoCopper coil vs Mirena: Which is right for you?
















1 Comment